Choroidal Neovascularization Market | Industry Insights By Growth, Emerging Trends And Forecast By 2032

The latest report by IMARC Group, titled “Choroidal Neovascularization Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032“, The global choroidal neovascularization market size reached US$ 6.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 11.6 Billion by 2032, exhibiting a growth rate (CAGR) of 6.4% during 2024-2032.

Choroidal neovascularization (CNV) is a condition marked by the anomalous development of new blood vessels within the choroid layer of the eye, situated just beneath the retina. This ailment is of notable concern in ophthalmology due to its potential to result in significant vision impairment, often associated with age-related macular degeneration (AMD). CNV arises when these aberrant blood vessels breach the Bruch's membrane, a delicate barrier that separates the choroid from the retina, causing the leakage of fluid or blood into the macula—the central region of the retina responsible for clear and precise vision. The accumulation of fluid and blood disrupts the normal macular function, leading to vision distortion or blurring. CNV may present in various forms, including classic CNV, occult CNV, and minimally classic CNV.

Choroidal Neovascularization Market Trends and Drivers:

The market is experiencing notable advancements and expansion due to the aging demographic in various regions worldwide. With age-related macular degeneration being a prevalent condition among older individuals, particularly contributing to CNV, there's a growing need for effective diagnosis and treatment solutions. As the global population ages further, the demand for such solutions is anticipated to rise, offering opportunities for market players. Furthermore, progressions in diagnostic and imaging technologies are augmenting early CNV detection. Imaging techniques like optical coherence tomography (OCT) and fluorescein angiography (FA) facilitate precise and prompt diagnosis, enabling timely interventions such as anti-vascular endothelial growth factor (anti-VEGF) therapies. Companies specializing in innovative diagnostic tools and imaging equipment for CNV stand to benefit from this trend. Additionally, the increasing emphasis on personalized medicine is impacting the CNV market. Tailoring treatment strategies based on individual patient characteristics, including genetic predispositions and biomarkers, is gaining traction. This personalized approach aims to optimize treatment outcomes while minimizing potential adverse effects. Moreover, regulatory bodies and healthcare institutions are stressing the importance of patient accessibility to effective CNV treatments, involving initiatives to streamline therapy approval processes and enhance reimbursement mechanisms.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/choroidal-neovascularization-market/requestsample

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Product Type:

  • Intravenous
  • Intravitreal
     

Breakup by Type of Diagnosis:

  • Fluorescein Angiography (FA)
  • Indocyanine Green (ICG) Angiography
  • Spectral Domain Optical Coherence Tomography (OCT)
  • Others

Breakup by Treatment Type:

  • Angiogenesis Inhibitors Injection
  • Photodynamic Therapy
  • Laser photocoagulation
  • Low-dose Radiation Therapy
  • Surgery

Breakup by Application:

  • Extreme Myopia
  • Malignant Myopic Degeneration
  • Age-Related Developments

Market Breakup by Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

Competitive Landscape with Key Player:

  • Bausch Health Companies Inc.
  • Bayer AG
  • Gilead Sciences Inc.
  • F. Hoffmann-La Roche AG
  • MaaT Pharma, Novartis AG
  • Pfizer Inc.
  • Quark Pharmaceuticals Inc. (SBI ALApharma Co. Limited)
  • Regeneron Pharmaceuticals Inc.
  • Sanwa Kagaku Kenkyusho Co. Ltd. (Suzuken Co. Ltd.).

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145 |United Kingdom: +44-753-713-2163

 

Comments

Popular posts from this blog

Portable Blenders Market Size, Share, Growth, Trends and Analysis 2025-2033

Hazelnut Market Trends 2024 | Growth, Share, Size and Future Scope 2032

Soundbar Market Report Presents An Inside Look At Upcoming Trends, Growth And Forecast Till 2032